TP53 and prostate cancer: In various p53-expressing ovarian cancer cells ES-2 and PA-1 and prostate cancer cells LNCaP, 22RV1, and PC3, a direct correlation between EA-induced caspase 3 activation and PARP cleavage in a dose-dependent manner (10–100 μmol/L) was demonstrated, culminating in a significant increase in the number of apoptotic cells [56,124].